"A verdadeira viagem de descoberta não consiste em procurar novas paisagens mas em ver com novos olhos"

.......

(Marcel Proust)

capa-verde-1.tif
e-book

Ensaios de binding: fundamentos teóricos, aspectos práticos e aplicações no desenvolvimento de fármacos

Apostila

Historia da Farmacologia: das origens à era moderna

Capa-livro-farmaco.jpg
Livro-Texto: Farmacologia

Cap.1: Introdução à Farmacologia: aspectos históricos

Glossário de Farmacologia

1. Medicamento (vs Remédio) e Fármaco (vs droga) - Newsletter SBFTE (Junho 2013)

2.Efeito adverso vs efeito colateral - Newsletter SBFTE (Setembro 2013)

3; Sinergismo vs. aditividade e potencialização - Newsletter SBFTE (Março 2014)

4; Biodisponibilidade e Absorção – Newsletter SBFTE (Junho 2015)

5. Eficácia, Efetividade e Eficiência – Newsletter SBFTE (Setembro 2015)

6. Doenças Negligenciadas vs Doenças Raras e Fármacos Órfãos – Newsletter SBFTE (Dezembro 2015)

7. Tempo de residência do complexo fármaco-receptor – Newsletter SBFTE (Abril 2016)

8. Alosterismo, sítio ortostérico, sítio alostérico, modulador alosterico e ligante bitópico – Newsletter SBFTE (Julho 2016)

9. Seletividade funcional / Agonismo tendencioso – Newsletter SBFTE (Novembro 2016)

10. Seletividade v.s. especificidade – Fármacos multi-alvo v.s. promíscuos

11. Farmacogenética e Farmacogenômica

12. Tipos de Antagonismo

13. Hit, lead, drug candidate / Substância ativa, protótipo, candidato a fármaco

14. Descoberta e Desenvolvimento de fármacos

15. Coeficiente de Hill

16. Reposicionamento de fármacos

17. Medicina baseada em evidências e ECCRs (Estudos      Clínicos Controlados e Randomizados)

18. Polifarmácia

19. ”Decoy receptor” / Receptor decoy (receptor isca)

20. Biomarcador e desfecho substituto (“surrogate endpoint”)

Últimas Publicações Acadêmicas

2020

Issy AC, Pedrazzi JFC, van Oosten ABS, Checheto T, Silva RR, Noël F, Del-Bel. Effects of Doxycycline in Swiss Mice Predictive Models of Schizophrenia. eurotox Res. 2020 Sep 15. doi: 10.1007/s12640-020-00268-

Bray M, Rayner C, Noël F, Jans D, Wagstaff K. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses. Antiviral Res. 178: 104805, June 2020.

Noël F, Lima J. Pharmacological aspects and clues for the rationale use of Chloroquine/Hydroxychloroquine facing the therapeutic challenges of COVID-19 pandemic. Lat Am J Clin Sci Med Technol 2(2):28-34, 2020.

da Silva VD, Silva RR, Neto JG, López-Corcuera B, Guimarães MZ, Noël F, Buarque CD. New α-hydroxy-1,2,3-triazoles and 9H-fluorenes-1,2,3-triazoles: synthesis and evaluation as Glycine Transporter 1 Inhibitors. J. Braz. Chem. Soc. 31(6): 1258-1269, 2020.

Azalim P, do Monte FM, Rendeiro MM, Liu X, O’Doherty GA, Fontes CF,  Leitão SG, Quintas LEM, Noël F. Conformational states of the pig kidney Na+/K+-ATPase differently affect bufadienolides and cardenolides: a directed structure-activity and structure-kinetics study. Biochem. Pharmacol. 171:113679, 2020.

 

2019

Nascimento-Viana JB, Alcántara-Hernández R, Oliveira-Barros E, Castello Branco LA, Feijó PR, Romeiro LAS, Nasciutti LE, Noël F, García-Sáinz JA, Silva CLM. The α1-adrenoceptor-mediated human hyperplastic prostate cells proliferation is impaired by EGF receptor inhibition. Life Sci. Nov 12:117048, 2019.

Silva RR, Parreiras-e-Silva LT, Pompeu TET, Duarte DA, Fraga CAM, Barreiro EJ, Menegatti R, Costa-Neto CM, Noël F. Evaluation of functional selectivity of haloperidol, clozapine, and LASSBio-579, an experimental compound with antipsychotic-like actions in rodents, at G protein and arrestin signaling downstream of the dopamine D2 receptor. Frontiers in Pharmacology, 10:628, 2019.

 

Quaresma B.M.C.S., Pimenta A.R., da Silva A.C., Pupo A.S., Romeiro L.A.S., Silva C.L.M., Noël F. Revisiting the pharmacodynamics uroselectivity of Alpha1-Adrenergic Receptor Antagonists.  J. Pharmacol. Exp. Ther. 371:106-112, 2019.

 

2018

Noël F, Azalim P, do Monte FM, Quintas LEM, Katz A, Karlish SJD. Revisiting the binding kinetics and inhibitory potency of cardiac glycosides on Na+,K+-ATPase (a1b1): methodological considerations. J.  Pharmacol. Toxicol. Methods  94(Pt 2):64-72, 2018 .

 

Amaral LS, Ferreira JM, Predes D, Abreu JG, Noël F, Quintas LEM. Telocinobufagin and Marinobufagin Produce Different Effects in LLC-PK1 Cells: A Case of Functional Selectivity of Bufadienolides. Int. J. Mol. Sci. 19: 2769, 2018.

 

Costa FBCortez APde Ávila RIde Carvalho FSAndrade WMda Cruz AFReis KBMenegatti RLião LMRomeiro LASNoël FFraga CAMBarreiro EJSanz GRodrigues MFVaz BGValadares MC. The novel piperazine-containing compound LQFM018: Necroptosis cell death mechanisms, dopamine D4 receptor binding and toxicological assessment. Biomed Pharmacother. 102:481-493, 2018.

Brito AF, Patrícia C. C. S. Braga PCCS, Moreira LKS, Silva DM, Silva DPB, Sanz G,  Vaz BG,  de Carvalho FS, Lião LM, Silva RR, Noël F,  Neri HFS, Ghedini PC, de Carvalho MF, Gil ES, Costa EA, Menegatti R. A new piperazine derivative: 1-(4-(3,5-di-tert-butyl-4-hydroxybenzyl) piperazin-1-yl)-2-methoxyethan-1-one with antioxidant and central activity. Naunyn Schmied. Arch. Pharmacol. 391:255–269, 2018.

2017

Carvalho VF, Ferreira TPT, De Arantes ACS, Noël F, Roberta Tesch R, Sant ´Anna CMR, Barreiro EJ, Fraga CAM, Silva PMR, Martins MA. LASSBio-897 reduces lung injury induced by silica particles in mice: potential interaction with the A2A receptor. Front. Pharmacol. 8: 778, 2017.

 

Effects of cardiotonic steroids on isolated perfused kidney and NHE3 activity in renal proximal tubules. Godinho AN, Costa GT, Oliveira NO, Cardi BA, Uchoa DEA, Silveira ER, Quintas LEM, Noel FG, Fonteles MC, Carvalho KM, Santos CF, Lessa LMA, do Nascimento NRF. Biochim. Biophys. Acta. 1861(8):1943-1950, 2017

LASSBio-1422: a new molecular scaffold with efficacy in animal models of schizophrenia and disorders of attention and cognition. Betti AH, Antonio CB, Pompeu TET, Thaise Martins TS, Herzfeldt V, Stolz ED, Fraga CAM, Barreiro EJ, Noël F, Rates SMK. Behav. Pharmacol. 28(1):48-62, 2017

 

2016

Na+-shift binding assay for estimation of the intrinsic efficacy of ligands at the A2A adenosine receptor. Noel F. & Monteiro do Monte, F. J.  Pharmacol. Toxicol. Methods 84:51-56, 2016.

ADME studies and preliminary safety pharmacology of LDT5, a lead compound for the treatment of Benign Prostatic Hyperplasia. Noël F, Nascimento-Viana J, Romeiro LA, Silva R, Lemes L, Oliveira A, Giorno T, Fernandes P, Silva CLM.  Braz. J. Biol. Med. Res. 49(12):e5542, 2016

 

Non-competitive Inhibitor of Nucleoside Hydrolase from Leishmania donovani Identified by Fragment-based Drug Discovery.  Alves MA, Nirma C, Moreira MM, Soares RO, Pascutti PG, Noël F, Costa PRR, Sant`Anna CM6, Barreiro EJ, Lima LM, Tinoc LW . RSC Advances 6:87738-87744, 2016.

Bufadienolides from parotoid gland secretions of Cuban toad Peltophryne fustiger (Bufonidae): inhibition of human kidney Na+/K+-ATPase activity. Perera Córdova WH, Leitão SG, Cunha-Filho G, Bosch RA, Alonso IP, Pereda-Miranda R, Gervou R, Touza NA, Quintas LE, Noël F. Toxicon 110: 27-34, 2016.

 

New multi-target antagonists of α1A-, α1D-adrenoceptors and 5-HT1A receptors reduce human hyperplastic prostate cell growth and the increase of intraurethral pressure. Nascimento-Viana JB,  Carvalho AR,  Nasciutti LE, Alcantara-Hernandez R,  Chagas-Silva F, de Souza PAR, Romeiro LA, Adolfo Garcia-Sainz A, Noel F,  Silva CLM. J. Pharmacol. Exp. Ther. 356:212-222, 2016.